Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > News After The Close

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Sep 25, 2024 10:46pm

166 Views

Post# 36241493

RE:RE:RE:RE:RE:RE:RE:RE:News After The Close

It will be hard to value BTD as CGON has BTD for a single indication and is valued at $2.5- 3 Billion USD..If we hit $2 USD, that would be $480 million MC. Still dirt cheap next to CGON

CancerSlayer wrote:
Mikee3003 wrote: Don't kid yourself Tapps, if big pharma were drooling with all the woopie doo news releases of late they would snap us up in a heartbeat.....yet here we sit with a stock price that indicates end of the road is more likely than the kool aid gangs prediction of $2.00!!!!

Big Pharma generally wants to see at least 1 BTD in hand for a single indication with unmet need that has a decent market size (1B+) & additional growth potential. If we are granted a BTD, our ACT certainly fits that criteria.

However, a single BTD for a single indication won't get us to $2...very unlikely on this exchange imo. I'd be happy to see us reach .50 to $1, which may be more realistic (esp. on the lower end of range). What would give more significant value is having that BTD + adequate cash reserves ($10M+) to allow for further development/preliminary clinical validation in at least one other indication in a desirable/unmet market (i.e. as a combo or monotherapy in NSCLC, GBM, etc.).

I don't mind if we were to get a small(er) bump in sp after BTD...as long as in the near term we can obtain somewhat friendly cash ($10M+)...adequate reserves is just as important of a value-driver as one BTD for a small, single BTD biotech company. All imo...